Scienmag

AUGUST 12, 2020

Researchers in China have taken the first step towards a new way of treating gastric wounds by using a microrobot combined with the new concept of “in situ in vivo bioprinting” to carry out tissue repair inside the body.

In-Vivo 72

In-Vivo Research Engineer Medicine 72

Pharmaceutical Technology

OCTOBER 25, 2022

BioMed X has entered a research partnership with Sanofi to leverage artificial intelligence (AI) for drug development. Under the joint research project, a new research team will be set up at the BioMed X Institute in Heidelberg, Germany. The companies will select a varied group of skilled researchers for the project.

Development 246

Development Drugs In-Vivo Engineer 246

Pharmaceutical Technology

NOVEMBER 22, 2022

Umoja Biopharma has signed a research agreement with IASO Biotherapeutics (IASO Bio) to develop off-the-shelf therapies for haematological malignancies. In the initial stage, the partnership will focus on acute myeloid leukaemia (AML) to boost accessibility to patients.

Development 276

Development In-Vivo Engineer Clinical Trials 276

Medical Xpress

MAY 16, 2023

That was the case when Thilini Gamage was to carry out one of the studies in her doctoral work with Professor Eirik Frengen at the Institute of Clinical Medicine, University of Oslo. They study gene variation and mutations that cause rare genetic diseases. A mutation is a permanent change in the genetic material.

In-Vitro 98

In-Vitro In-Vivo Genetic Disease Genetics 98

pharmaphorum

MARCH 19, 2024

Achieve Safe & Targeted In Vivo Delivery of Payloads with Clarity in Regulations & Appropriate Models to Advance the Next Frontier of In Vivo Editing from Research to Clinic

In-Vivo 52

In-Vivo Gene Editing Engineer Gene 52

Pharmaceutical Technology

MAY 23, 2023

Last month, the South San Francisco, California-headquartered company presented preclinical data on its KRAS inhibitor pipeline, which includes QTX3034 and QTX3046 at the Annual Meeting of the American Association for Cancer Research in Orlando, Florida. Quanta Therapeutics has raised $50.7 billion in 2029.

Research 130

Research In-Vivo Sales Gene 130

XTalks

OCTOBER 9, 2024

In this episode, Vera spoke with Tim Culp, PhD, Vice President of Research and Development at Interius BioTherapeutics, a Philadelphia-based biotech company. Dr. Culp completed a PhD from the Pennsylvania State University, College of Medicine for his research on human papillomaviruses.

In-Vivo 59

In-Vivo Life Science Doctor Doctors 59

Pharmaceutical Technology

AUGUST 18, 2022

An ex-vivo lentiviral vector (LVV) gene therapy, Zynteglo’s every dose is made by genetically modifying the bone marrow stem cells of the patient to produce functional beta-globin. thalassemia in adult and paediatric patients. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Gene Therapy 246

Gene Therapy Gene Genotype In-Vivo 246

Scienmag

SEPTEMBER 29, 2021

Furthermore, the current understanding of beta cell function is mostly derived from studies of ex vivo isolated islets in rodent […]. However, the highly regulated process of insulin secretion, especially its molecular features and the stimuli behind this process have not yet been fully understood.

In-Vivo 52

In-Vivo Insulin Development Regulation 52

Medical Xpress

MAY 15, 2023

A new research paper, titled "In vitro and in vivo effects of zoledronic acid on senescence and senescence-associated secretory phenotype markers," was published on the cover of Aging

In-Vivo 98

In-Vivo In-Vitro Research 98

Pharmaceutical Technology

FEBRUARY 23, 2023

Moderna has entered a strategic research and development partnership with ElevateBio’s Life Edit Therapeutics to discover and develop new in-vivo mRNA gene editing therapies. Under the deal, both companies will partner on the research and preclinical studies, which will be funded by Moderna.

Gene Editing 147

Gene Editing Gene In-Vivo Gene Therapy 147

Pharmaceutical Technology

NOVEMBER 9, 2022

ProPhase Labs’ wholly owned subsidiary ProPhase BioPharma has entered a two-year collaboration agreement with Dana-Farber Cancer Institute for further research and development of Linebacker-1 (LB-1). The partnership deal provides for first and second-year research plans.

In-Vivo 130

In-Vivo Development In-Vitro Scientist 130

BioPharma Reporter

NOVEMBER 10, 2022

EdiGene Biotechnology USA has moved into a new Research & Development Center in Waltham, Mass. to advance its proprietary LEAPER tech into in vivo RNA editing therapies: with an initial focus on ophthalmology and the central nervous system.

In-Vivo 96

In-Vivo RNA Development Research 96

Pharmaceutical Technology

MAY 5, 2023

Under the collaborative research and development agreement (CRADA), respirable dry powder formulations of HMW-HA will be developed for prevention and treatment. This follows earlier research which demonstrated that HMW-HA yielded dry powder formulations with desirable aerosol performance when formulated with thin film freezing technology.

Development 162

Development In-Vivo In-Vitro Engineer 162

Pharmaceutical Technology

MAY 17, 2023

Scribe Therapeutics has entered a strategic collaboration with Eli Lilly and Company subsidiary Prevail Therapeutics for accelerating in vivo CRISPR-based therapies to target the causes of serious neurological and neuromuscular diseases. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Genetics 130

Genetics Medicine In-Vivo Gene Therapy 130

Pharmaceutical Technology

MAY 12, 2023

BioNTech has ended its research collaboration with Matinas after its oral mRNA vaccine failed to demonstrate preclinical activity. The in vivo study, conducted in mice, involved a phosphatidylserine-containing nano-formulation of mRNA supplied by BioNTech, distinct from traditional lipid nanocrystals (LNCs).

Vaccination 130

Vaccination Vaccine In-Vivo In-Vitro 130

BioTech 365

JANUARY 10, 2022

Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a … Continue reading →

In-Vivo 40

In-Vivo Research 40

Scienmag

NOVEMBER 12, 2020

A research team led by Prof. Gong Chen at Jinan University, Guangzhou, China recently reported the first non-human primate study demonstrating successful in vivo neural regeneration from brain internal glial cells for stroke repair. This work was […].

Gene Therapy 98

Gene Therapy In-Vivo Gene Research 98

Scienmag

JULY 21, 2021

Researchers from the UNIGE and the HUG have used information theory for the first time to monitor in vivo the development of resistance mechanisms to a cancer-targeted therapy. Credit: © R.Merat, Neoplasia 2021; 23 (8): 775-782.

In-Vivo 95

In-Vivo Development Research Medicine 95

pharmaphorum

JUNE 23, 2022

Novartis has shouldered its way into the in vivo gene editing category via a deal with US biotech Precision BioSciences, focused on a therapy for sickle cell disease (SCD). Other companies – notably Vertex Pharma/CRISPR Therapeutics and bluebird bio – are taking an ex vivo approach to SCD and thalassaemia and are much closer to market.

Gene Editing 97

Gene Editing In-Vivo Gene Sequencing Gene 97

BioTech 365

OCTOBER 25, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Intellia, LogicBio fuel hope for in vivo gene editing with new animal data in rare diseases: report.Intellia, LogicBio fuel hope for in vivo gene editing with new … Continue reading →

Gene Editing 40

Gene Editing In-Vivo Gene Research 40

Pharmaceutical Technology

FEBRUARY 15, 2023

Developing both in vivo and ex vivo gene editing medicines, Editas Medicine is primarily involved in the haematology and oncology therapy areas. However, not all innovations are equal and nor do they follow a constant upward trend. Editas Medicine is one of the most important players concerning innovation surrounding CRISPR nucleases.

In-Vivo 162

In-Vivo Genome Genomics Gene Editing 162

Pharmaceutical Technology

JULY 20, 2022

Roche will also make further payments to Avista during the collaboration’s research phase and clinical, sales-based milestone and royalty payments for resulting products. Avista's computationally steered, in vivo scAAVengr platform uses a high-throughput method with the integrated quantitative validation of new cell-specific AAVs.

Gene Therapy 147

Gene Therapy Gene Development In-Vivo 147

Pharmaceutical Technology

FEBRUARY 23, 2023

Innovation S-curve for artificial Intelligence in the pharmaceutical industry In-silico drug discovery is a key innovation area in artificial Intelligence Drug research starts with the discovery stage that involves in vivo and in vitro models to shortlist lead drug compounds.

Drugs 189

Drugs DNA In-Vivo In-Vitro 189

BioTech 365

APRIL 12, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Sanofi pays $160M for mRNA tech to reprogram T cells in vivo.Sanofi pays $160M for mRNA tech to reprogram T cells in vivo ntaylor Mon, 04/12/2021 – … Continue reading →

In-Vivo 40

In-Vivo Research 40

Pharmaceutical Technology

SEPTEMBER 14, 2022

As an autologous cell therapy, manufacturing the infusion product is a highly specialised process involving tumour harvest and the extraction and large-scale ex vivo expansion of TILs. Tumour-infiltrating lymphocyte (TIL) therapy has been investigated as a treatment modality for melanoma for almost 20 years. versus 21.4% respectively.

Immune Response 246

Immune Response In-Vivo Production Manufacturing 246

pharmaphorum

JANUARY 29, 2021

California-based Sangamo Therapeutics is one such company that believes in the powerful potential of in vivo genome editing and regulation, together known as genome engineering, and has built up a sizable preclinical pipeline of genome regulation treatments for diseases such as Huntington’s disease and Amyotrophic lateral sclerosis (ALS).

Gene Editing 145

Gene Editing Gene Gene Therapy In-Vivo 145

Scienmag

FEBRUARY 10, 2021

Diurnal in vivo xylem sap glucose and sucrose monitoring using implantable organic electrochemical transistor sensors Credit: Thor Balkhed Researchers at Linköping University, Sweden, have developed biosensors that make it possible to monitor sugar levels in real time deep in the plant tissues – something that has previously been impossible.

In-Vivo 85

In-Vivo Development Research 85

Pharmaceutical Technology

AUGUST 17, 2022

oRNA molecules have been demonstrated to possess increased stability in vivo compared to linear mRNA and can potentially create more quantities of therapeutic proteins within the body. . These programmes will include therapies and vaccines in infectious disease and oncology areas.

RNA 147

RNA Vaccination Vaccine In-Vivo 147

BioTech 365

MAY 1, 2021

Editas Medicine to Present Preclinical Data Demonstrating Advancements in In Vivo Gene Editing Approach for the Treatment of Genetic Ocular Diseases at the Association for Research in Vision and Ophthalmology Annual Meeting Editas Medicine to Present Preclinical Data Demonstrating Advancements … Continue reading →

Gene Editing 40

Gene Editing In-Vivo Genetics Gene 40

pharmaphorum

JULY 5, 2022

The two partners will take an in vivo approach to the problem of so-called sensorineural hearing loss (SNHL) looking at ways to replace sound-detecting hair cells in the inner ear (cochlea) that become damaged in this type of deafness. An estimated 1.57 Astellas is already working on other approaches to treating hearing loss.

In-Vivo 110

In-Vivo Bioinformatics Genetics Licensing 110

Pharmaceutical Technology

SEPTEMBER 29, 2022

Under the agreement, Sanofi will receive non-exclusive rights to Scribe’s CRISPR by Design platform of wholly-owned enzymes for developing ex vivo NK cell therapies. The alliance will leverage the CRISPR genome editing technologies of Scribe to facilitate in genetic modification of new natural killer (NK) cell therapeutics for cancer.

Development 130

Development In-Vivo Genome Genomics 130

Scienmag

JUNE 23, 2021

Martin Borch Jensen to present new research in the biology of aging at the world’s largest aging research for drug discovery conference Credit: Insilico Medicine Hong Kong Limited Wednesday, June 23, 2021, London — Martin Borch Jensen, PhD.,

In-Vivo 57

In-Vivo Research Drugs Medicine 57

Pharmaceutical Technology

MAY 10, 2023

CytoMed Therapeutics has signed a research collaboration deal with the University of Texas MD Anderson Cancer Center (MD Anderson) in the US to use gamma-delta T cells (gdTc) to treat acute myeloid leukaemia (AML) and breast cancer. MD Anderson leukaemia associate professor Venkata Lokesh Battula will lead the research study.

Gene Therapy 147

Gene Therapy In-Vivo In-Vitro Gene 147

Worldwide Clinical Trials

NOVEMBER 27, 2023

Casgevy, the commercial product formerly known as exa-cel, is administered by taking stem cells out of a patient’s bone marrow and editing a gene in the cells in a laboratory, with the modified cells then infused back into the patient after conditioning treatment to prepare the bone marrow. In June 2023, the U.S.

Gene Editing 189

Gene Editing Gene Gene Therapy In-Vivo 189

Pharmaceutical Technology

MARCH 24, 2023

Moderna Research and Early Development senior vice-president Rose Loughlin said: “Moderna continues to invest in innovative technology to enable us to develop a breadth of transformative medicines for patients. Both companies will use the partnership for advancing in vivo immune cell targeting as a new class of genetic medicines.

Genetics 130

Genetics Medicine Development In-Vivo 130

Pharmaceutical Technology

MAY 31, 2023

In vivo and in vitro pre-clinical studies demonstrated that CFT8919 provides wider coverage of on-target resistant mutations and intracranial activity, indicating its potential to be effective against brain metastases. The agreement will cover the Hong Kong special administrative region (SAR), the Macau SAR and Taiwan.

In-Vivo 130

In-Vivo Bioavailability In-Vitro Licensing 130